- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05162066
BCX9930 voor de behandeling van C3G, IgAN en PMN (RENEW) (RENEW)
Een open-label, veiligheids-, verdraagbaarheids- en proof-of-concept-onderzoek van orale BCX9930-therapie bij proefpersonen met C3G, IgAN of PMN
The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
Poitiers, Frankrijk
- Investigative Site
-
Toulouse, Frankrijk
- Investigative Site
-
-
-
-
-
Bari, Italië
- Investigative Site
-
Bergamo, Italië
- Investigative Site
-
Brescia, Italië
- Investigative Site
-
Turin, Italië
- Investigative Site
-
-
-
-
-
Barcelona, Spanje
- Investigative Site #1
-
Barcelona, Spanje
- Investigative Site #2
-
Madrid, Spanje
- Investigative Site #1
-
Madrid, Spanje
- Investigative Site #2
-
-
-
-
-
Oxford, Verenigd Koninkrijk
- Investigative Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Body weight ≥ 40 kilograms (kg)
- Primary diagnosis of C3G, IgAN, or PMN confirmed by central pathology review
- An estimated glomerular filtration rate (eGFR) ≥ 50 milliter per minute per 1.73 meter square (mL/min/1.73 m^2) (or ≥ 30 mL/min/1.73 m^2 after Data Monitoring Committee [DMC] recommendation)
- Receiving treatment with a stable, maximum recommended or maximum tolerated dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) for at least 60 days prior to the Day 1 Visit
- Documentation of current vaccinations against Neisseria meningitidis and Streptococcus pneumoniae or willingness to start vaccination series
Exclusion Criteria:
- Known congenital deficiency of C1s, C1r, C1q, C2, or C4
- History of hematopoietic cell transplant or solid organ transplant or anticipated candidate for transplantation
- Myocardial infarction or cerebrovascular accident within 30 days prior to screening, or current and uncontrolled clinically significant cardiovascular or cerebrovascular condition
- History of malignancy within 5 years prior to the screening visit
- Active serious bacterial, viral, or fungal infection or any other serious infection within 14 days of screening
- Treatment with any systemic immunosuppressive or immunomodulatory therapy within 90 days OR anti-CD20 antibody therapies (eg, rituximab) within 180 days prior to the screening visit
- Treatment with renin inhibitors (eg, aliskiren) or sodium-glucose-cotransporter 2 (SGLT2) inhibitors within 60 days prior to Day 1
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: C3G cohort
Approximately 14 eligible participants with C3G will be enrolled. |
Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily |
|
Experimenteel: IgAN cohort
Approximately 14 eligible participants with IgAN will be enrolled. |
Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily |
|
Experimenteel: PMN cohort
Approximately 14 eligible participants with PMN will be enrolled. |
Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percent Change From Baseline in 24-hour uPCR at Week 12
Tijdsspanne: Baseline, Week 12
|
Urinary protein/creatinine ratio (mg/mmol) =urine protein concentration (mg/dL)/ urine creatinine concentration (mmol/dL). Decrease of urinary protein/creatinine ratio means improvement of renal disease. |
Baseline, Week 12
|
|
Percent Change From Baseline in 24-hour uPCR at Week 24
Tijdsspanne: Baseline, Week 24
|
Urinary protein/creatinine ratio (mg/mmol) =urine protein concentration (mg/dL)/ urine creatinine concentration (mmol/dL). Decrease of urinary protein/creatinine ratio means improvement of renal disease. |
Baseline, Week 24
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Procentuele verandering ten opzichte van de uitgangswaarde in de 24-uurs urine-eiwituitscheiding
Tijdsspanne: Basislijn, weken 12, 24,
|
Basislijn, weken 12, 24,
|
|
|
Change From Baseline in Estimated Glomerular Filtration Rate
Tijdsspanne: Baseline, Weeks 12, 24
|
eGFR was calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula for participants ≥ 18 years old and by the bedside Schwartz formula for participants ≤ 18 years old. eGFR was reported in milliliter per minute per 1.73 per square meter (mL/min/1.73m^2). |
Baseline, Weeks 12, 24
|
|
Number of Participants With a Treatment-emergent Adverse Event (TEAE)
Tijdsspanne: From first dose up to safety follow-up period (Week 28)
|
An Adverse event (AE) was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug. |
From first dose up to safety follow-up period (Week 28)
|
|
Number of Participants Who Discontinued Due to a TEAE
Tijdsspanne: From first dose up to safety follow-up period (Week 28)
|
An AE was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug. |
From first dose up to safety follow-up period (Week 28)
|
|
Number of Participants Who Experienced a Treatment-emergent Serious Adverse Event (TESAE)
Tijdsspanne: From first dose up to safety follow-up period (Week 28)
|
An AE was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug. A serious adverse event (SAE) was an adverse event/reaction that results in any of the following outcomes:
|
From first dose up to safety follow-up period (Week 28)
|
|
Number of Participants Who Experienced a Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 TEAE
Tijdsspanne: From first dose up to safety follow-up period (Week 28)
|
An AE was any untoward medical occurrence has no causal relationship with the study drug or with the clinical study itself. It was an unfavorable & unintended sign, symptom, syndrome, or illness that developed or worsened during clinical study. TEAEs: AEs that started on or after first dose of treatment through 30 days after the last dose of study drug. All AEs were graded using the CTCAE Grades 1 through 5. Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL Grade 4: Life-threatening consequences; urgent intervention indicated Grade 5: Death Participants with Grades 3 or 4 AEs were reported |
From first dose up to safety follow-up period (Week 28)
|
|
Number of Participants Who Experienced a CTCAE Treatment-emergent Grade 3 or 4 Laboratory Abnormality
Tijdsspanne: From first dose up to safety follow-up period (Week 28)
|
Treatment-emergent Laboratory Abnormality were defined as an event that started on or after the first dose of study treatment through 30 days after the last dose of study drug. CTCAE Grades for laboratory abnormalities include: Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death Participants with Grades 3 or 4 laboratory abnormality were reported. |
From first dose up to safety follow-up period (Week 28)
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Carla M Nester, MD, MSA, FASN, University of Iowa Stead Family Children's Hospital
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Mannelijke urogenitale ziekten
- Nier Ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Auto-immuunziekten
- Ziekten van het immuunsysteem
- Glomerulonefritis
- Nefritis
- Glomerulonefritis, IGA
- Glomerulonefritis, membraanachtig
- Glomerulonefritis, Membranoproliferatief
Andere studie-ID-nummers
- BCX9930-211
- 2020-005855-19 (EudraCT-nummer)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .